Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)

📈 Biogen Inc. (BIIB) is upgraded to a 'Buy' rating due to successful strategic acquisitions and pipeline progress offsetting multiple sclerosis portfolio erosion.

💰 Q2 revenue grew 3% year-over-year, supported by Apellis acquisition, rare disease growth, and Alzheimer's collaboration initiatives.

🧠 LEQEMBI is gaining global traction, serving as a key driver for the company's current financial performance.

🔬 Felzartamab's multi-indication potential and upcoming pivotal trial readouts are identified as underpinning long-term growth prospects.

💵 DCF analysis suggests BIIB is undervalued in the low-$200s, with valuation highly sensitive to growth acceleration above current 2-3% projections.

🛡️ The company is successfully overcoming loss-of-exclusivity (LOE) troubles within its multiple sclerosis portfolio.

Bullish Signals
  • Biogen received a 'Buy' rating upgrade, signaling strong analyst confidence in the company's strategic direction and financial recovery.
  • Q2 revenue achieved a 3% year-over-year growth rate, demonstrating resilience and effective execution across key segments.
  • LEQEMBI is gaining global traction, indicating successful market penetration for a major Alzheimer's therapy.
  • Felzartamab presents multi-indication potential, offering a diversified pipeline strategy to drive future revenue streams.
  • Upcoming pivotal trial readouts for Felzartamab are expected to further validate the company's long-term growth thesis.
  • DCF analysis concludes that Biogen is undervalued in the low-$200s range, presenting a potential buying opportunity.
Full Analysis
Biogen Inc. (BIIB) has been upgraded to a 'Buy' rating as the company executes a strategic turnaround, with recent acquisitions and pipeline advancements offsetting erosion in its multiple sclerosis portfolio. The Q2 financial report highlighted a 3% year-over-year revenue growth, driven by contributions from Apellis, rare disease segments, and Alzheimer's collaborations, alongside strong performance in LEQEMBI which is gaining global traction. Beyond immediate financial results, the article highlights significant long-term growth prospects anchored by Felzartamab's multi-indication potential and upcoming pivotal trial readouts. The analysis suggests that Biogen is successfully navigating loss-of-exclusivity (LOE) challenges in its MS business while leveraging new therapeutic areas to drive future value. A discounted cash flow (DCF) analysis indicates that Biogen is currently undervalued, with a target price in the low-$200s. The valuation model notes high sensitivity to growth acceleration, suggesting that performance exceeding current 2-3% projections would materially enhance the stock's attractiveness.